IL146868A0 - A pharmaceutical composition containing an igf-i/igfbp-3 complex - Google Patents

A pharmaceutical composition containing an igf-i/igfbp-3 complex

Info

Publication number
IL146868A0
IL146868A0 IL14686800A IL14686800A IL146868A0 IL 146868 A0 IL146868 A0 IL 146868A0 IL 14686800 A IL14686800 A IL 14686800A IL 14686800 A IL14686800 A IL 14686800A IL 146868 A0 IL146868 A0 IL 146868A0
Authority
IL
Israel
Prior art keywords
igfbp
complex
type
igf
pharmaceutical composition
Prior art date
Application number
IL14686800A
Other languages
English (en)
Original Assignee
Celtrix Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharma filed Critical Celtrix Pharma
Publication of IL146868A0 publication Critical patent/IL146868A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
IL14686800A 1999-06-04 2000-05-23 A pharmaceutical composition containing an igf-i/igfbp-3 complex IL146868A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/326,189 US6040292A (en) 1999-06-04 1999-06-04 Methods for treating diabetes
PCT/US2000/014163 WO2000074710A2 (en) 1999-06-04 2000-05-23 Methods for treating diabetes

Publications (1)

Publication Number Publication Date
IL146868A0 true IL146868A0 (en) 2002-08-14

Family

ID=23271175

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14686800A IL146868A0 (en) 1999-06-04 2000-05-23 A pharmaceutical composition containing an igf-i/igfbp-3 complex

Country Status (15)

Country Link
US (1) US6040292A (de)
EP (1) EP1183042B1 (de)
JP (1) JP2003501397A (de)
KR (1) KR100694737B1 (de)
CN (1) CN1235637C (de)
AT (1) ATE271880T1 (de)
AU (1) AU780400B2 (de)
CA (1) CA2373281C (de)
DE (1) DE60012517T2 (de)
ES (1) ES2222208T3 (de)
IL (1) IL146868A0 (de)
MX (1) MXPA01013384A (de)
NO (1) NO324117B1 (de)
WO (1) WO2000074710A2 (de)
ZA (1) ZA200110408B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
CA2630062C (en) * 2000-07-03 2014-10-14 Bristol-Myers Squibb Company Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
EP1455807A2 (de) * 2000-09-19 2004-09-15 Bioexpertise, Llc Verfahren für die verwendung von igf-bindunsprotein zur selektiven sensibilisierung von zielzellen in vivo
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20040077679A1 (en) * 2002-07-29 2004-04-22 Cincotta Anthony H. Therapeutic treatment for the metabolic syndrome and type 2 diabetes
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
CN104206651A (zh) * 2004-12-30 2014-12-17 希尔氏宠物营养品公司 用于猫消费的组合物
WO2008130315A1 (en) * 2007-04-18 2008-10-30 Premacure Ab Method and product for treatment and/or prevention of complications of prematurity
WO2010096125A1 (en) * 2008-10-29 2010-08-26 The Rockefeller University Methods and kits for treating disease by administering insulin-like growth factor binding protein-2
RU2537142C2 (ru) 2009-04-01 2014-12-27 Дженентек, Инк. Лечение нарушений, связанных с инсулинорезистентностью
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
KR101847669B1 (ko) 2010-08-16 2018-05-24 알러간, 인코포레이티드 알파-2b 아드레날린성 수용체 효현제로 조절 t 세포를 활성화시키는 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200509A (en) * 1987-04-06 1993-04-06 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
GB9217696D0 (en) * 1992-08-20 1992-09-30 Agricultural & Food Res Use of specific binding molecules
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
JPH08500123A (ja) * 1993-01-25 1996-01-09 ザ ベス イスラエル ホスピタル アソシエイション Ｉｇｆ−ｉ感受性細胞のバリヤー特性の修飾方法，診断方法及びスクリーニング方法
US5563046A (en) * 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
ATE190499T1 (de) * 1993-08-03 2000-04-15 Celtrix Pharma Methode zur behandlung von reproduktionserkrankungen
ATE226958T1 (de) * 1993-09-20 2002-11-15 Celtrix Pharma Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex
AU693489B2 (en) * 1993-11-15 1998-07-02 Celtrix Pharmaceuticals, Inc. Method of treating neurological disorders
AU690941B2 (en) * 1993-11-15 1998-05-07 Celtrix Pharmaceuticals, Inc. Method of treating renal disease by administering IGF-I and IGFBP-3
WO1996002565A1 (en) * 1994-07-20 1996-02-01 Celtrix Pharmaceuticals, Inc. Igf/igfbp complex for promoting bone formation and for regulating bone remodeling
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes

Also Published As

Publication number Publication date
ES2222208T3 (es) 2005-02-01
HK1044895A1 (en) 2002-11-08
US6040292A (en) 2000-03-21
JP2003501397A (ja) 2003-01-14
CN1235637C (zh) 2006-01-11
CA2373281A1 (en) 2000-12-14
DE60012517D1 (de) 2004-09-02
EP1183042A2 (de) 2002-03-06
CA2373281C (en) 2010-01-12
KR20020020723A (ko) 2002-03-15
ATE271880T1 (de) 2004-08-15
NO20015932L (no) 2002-01-31
WO2000074710A2 (en) 2000-12-14
NO20015932D0 (no) 2001-12-04
AU5041100A (en) 2000-12-28
ZA200110408B (en) 2003-03-19
MXPA01013384A (es) 2003-09-04
WO2000074710A3 (en) 2001-06-28
EP1183042B1 (de) 2004-07-28
CN1387440A (zh) 2002-12-25
AU780400B2 (en) 2005-03-17
NO324117B1 (no) 2007-08-27
DE60012517T2 (de) 2005-08-04
KR100694737B1 (ko) 2007-03-14

Similar Documents

Publication Publication Date Title
ZA200110408B (en) Methods for treating diabetes.
HUT68525A (en) Pharmaceutical compositions of prolonged delivery, containing peptides
AU3173297A (en) Exendin analogues, processes for their preparation and medicaments containing them
SG127714A1 (en) Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes
WO2002065985A3 (en) Methods of treating diabetes mellitus
EP0997151A3 (de) Methode zur Verabreichung von Peptiden mit insulinotroper Wirkung
MX9504380A (es) Composiciones, analogos de peptido insulinotropico semejante a glucagon y metodos de uso de los mismos.
NZ504258A (en) Exendin 3 and 4 agonist compounds for the treatment of diabetes
MY137350A (en) Glucagon-like peptide-1 analogs
AU2610899A (en) N-terminally modified glp-1 derivatives
MXPA05007470A (es) Metodo para reducir la morbilidad y mortalidad cardiovascular en pacientes prediabeticos y pacientes con diabetes de tipo 2.
AU3888893A (en) Use of a peptide
BR0212080A (pt) composto de glp-1, método de estimulação de receptor de glp-1 em um indivìduo necessitando de tal estimulação, e, uso de um composto de glp-1
AU2003234529A8 (en) Glp-1 gene delivery for the treatment of type 2 diabetes
ZA200606153B (en) Intranasal administration of glucose-regulating peptides
GR3036901T3 (en) Treatment of partial growth hormone insensitivity syndrome
NO940180D0 (no) Anvendelse av IGF-I
ZA942980B (en) Recombinant viruses and their use in gene therapy.
CA2270177A1 (en) Transdermal administration of ment
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
MY155219A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
BG104059A (en) Diabetes treatment with rosiglytazone and insulin
BG104139A (en) Diabetes treatment with thizolidindion and sulphonylurea
CA2252560A1 (en) Treatment of partial growth hormone insensitivity syndrome
WO2001047509A3 (en) Composition for the treatment diabetes mellitus containing an insuline sensitizer and agent used in the treatment of cardiac conditions

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees